All In Biotech

Drug Trial Radar · NCT01146652

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,023

Actual

Start

Jun 21, 2010

Primary completion

Dec 31, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jun 17, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Main Study: Primary Objective: Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA). Secondary Objective: Assess the long term efficacy of sarilumab in participants with RA. Sub-Study: This phase 3, open label sub-study was aimed to assess the usability of PFS-S when used by participants with moderate or severe RA, or their professional or non-professional healthcare providers in an unsupervised real-world situation. To mimic the real-world practice, the sub-study was incorporated into the LTS11210 study without additional visits compared to the scheduled visits in the main study. The duration of this sub-study was 12 weeks.

Conditions

  • Rheumatoid Arthritis

Interventions

  • SAR153191 (REGN88)Drug

    Pharmaceutical form: solution Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)
  2. Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36
  3. Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36
  4. Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36
  5. Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36

Locations

335 sites in 40 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840070

    Anniston, Alabama

  • Investigational Site Number 840138

    Birmingham, Alabama

  • Investigational Site Number 840152

    Huntsville, Alabama

  • Investigational Site Number 840072

    Gilbert, Arizona

  • Investigational Site Number 840141

    Glendale, Arizona

  • Investigational Site Number 840134

    Fullerton, California

  • Investigational Site Number 840008

    La Jolla, California

  • Investigational Site Number 840135

    San Diego, California

  • Investigational Site Number 840021

    Santa Maria, California

  • Investigational Site Number 840100

    Stanford, California

  • Investigational Site Number 840049

    Upland, California

  • Investigational Site Number 840151

    Colorado Springs, Colorado

  • Investigational Site Number 840130

    Lewes, Delaware

  • Investigational Site Number 840153

    Aventura, Florida

  • Investigational Site Number 840050

    Clearwater, Florida

  • Investigational Site Number 840033

    Fort Lauderdale, Florida

  • Investigational Site Number 840041

    Gainesville, Florida

  • Investigational Site Number 840067

    Jupiter, Florida

  • Investigational Site Number 840048

    Miami, Florida

  • Investigational Site Number 840024

    Naples, Florida

  • Investigational Site Number 840006

    Orlando, Florida

  • Investigational Site Number 840128

    Ormond Beach, Florida

  • Investigational Site Number 840063

    Palm Harbor, Florida

  • Investigational Site Number 840155

    Palm Harbor, Florida

  • Investigational Site Number 840060

    Sarasota, Florida

  • Investigational Site Number 840140

    Tampa, Florida

  • Investigational Site Number 840126

    Vero Beach, Florida

  • Investigational Site Number 840003

    Atlanta, Georgia

  • Investigational Site Number 840028

    Decatur, Georgia

  • Investigational Site Number 840027

    Marietta, Georgia

  • Investigational Site Number 840018

    Idaho Falls, Idaho

  • Investigational Site Number 840046

    Chicago, Illinois

  • Investigational Site Number 840052

    Kansas City, Kansas

  • Investigational Site Number 840230

    Elizabethtown, Kentucky

  • Investigational Site Number 840015

    Lexington, Kentucky

  • Investigational Site Number 840120

    Baton Rouge, Louisiana

  • Investigational Site Number 840109

    Lake Charles, Louisiana

  • Investigational Site Number 840055

    Frederick, Maryland

  • Investigational Site Number 840013

    Wheaton, Maryland

  • Investigational Site Number 840154

    Boston, Massachusetts

Showing 40 of 335 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.